Sarah J. Kennedy

Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

John V. Heymach, Bruce E. Johnson, Diane Prager et al. · Journal of Clinical Oncology · 2007 · 292 citations

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

Ronald B. Natale, David Bodkin, Ramaswamy Govindan et al. · Journal of Clinical Oncology · 2009 · 226 citations · Full text

Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment

V. Deshmukh, Alyssa L. O'Green, Carine Bossard et al. · Osteoarthritis and Cartilage · 2019 · 185 citations · Full text

ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial

Ronald B. Natale, David Bodkin, Ramaswamy Govindan et al. · Journal of Clinical Oncology · 2006 · 109 citations

Receiving Gefitinib, Cancer Management, Pharmacotherapy +18

Identification of a Survival-Promoting Peptide in Medium Conditioned by Oxidatively Stressed Cell Lines of Nervous System Origin

Timothy J. Cunningham, Lisa M. Hodge, David J. Speicher et al. · Journal of Neuroscience · 1998 · 79 citations · Full text